Freedom to Heal Act of 2025

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 6434 Introduced in House (IH)] <DOC> 119th CONGRESS 1st Session H. R. 6434 To establish a special registration under the Controlled Substances Act for schedule I eligible investigational drugs under the Federal Right to Try law. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES December 4, 2025 Ms. Dean of Pennsylvania (for herself, Ms. Mace, Mr. Correa, Mr. Khanna, Mr. Lieu, Mr. Crenshaw, Mr. Bergman, and Mr. Luttrell) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned _______________________________________________________________________ A BILL To establish a special registration under the Controlled Substances Act for schedule I eligible investigational drugs under the Federal Right to Try law. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Freedom to Heal Act of 2025''. SEC. 2. SPECIAL REGISTRATION REQUIREMENTS RELATED TO RIGHT TO TRY. Section 303 of the Controlled Substances Act (21 U.S.C. 823) is amended by adding at the end the following: ``(p) Special Registration for Schedule I Eligible Investigational Drugs Under Right To Try.-- ``(1) Definitions.--In this subsection, the terms `eligible investigational drug' and `eligible patient' have the meanings given those terms in section 561B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb-0a). ``(2) Special registration process.--The Attorney General shall register physicians to directly administer eligible investigational drugs in schedule I to eligible patients under section 561B of the